Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-08
2009-10-27
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000
Reexamination Certificate
active
07608634
ABSTRACT:
The present invention is directed to novel substituted pyrroline compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5624949 (1997-04-01), Heath, Jr. et al.
patent: 5721245 (1998-02-01), Davis et al.
patent: 6037475 (2000-03-01), Faul et al.
patent: 6479490 (2002-11-01), Gong et al.
patent: 6849643 (2005-02-01), Zhang
patent: 6987110 (2006-01-01), Zhang
patent: 7125878 (2006-10-01), Zhang
patent: 2004/0192718 (2004-09-01), Zhang
patent: 2004/0259928 (2004-12-01), Zhang
patent: 2005/0004201 (2005-01-01), Zhang
patent: 2005/0004202 (2005-01-01), Zhang
patent: 2006/0205762 (2006-09-01), Zhang
patent: 2006/0205763 (2006-09-01), Zhang
patent: 1057484 (2000-12-01), None
patent: 1120414 (2001-08-01), None
patent: WO 91/13071 (1991-09-01), None
patent: WO 9517182 (1995-06-01), None
patent: WO 9811102 (1998-03-01), None
patent: WO 00/06564 (2000-02-01), None
patent: WO 00/21927 (2000-04-01), None
patent: WO 02/10158 (2002-02-01), None
patent: WO 02/38561 (2002-05-01), None
patent: WO 0246183 (2002-06-01), None
U.S. Appl. No. 11/528,092, filed Sep. 27, 2006, Zhang.
PCT Search Report Dated Oct. 8, 2003 for PCT/US03/17569.
International J. Pharm., 1986, 33, 201-217.
J. Pharm Sci., 1977, Jan. 66 (1), p. 1.
P Xia et al, J. Clin Invest., 1996, 98, 2018.
H. Ishii et al, J. Mol. Med., 1998, 76, 21.
Inoguchi et al, Proc. Natl. Acad. Sci., USA, 1992, 89, 11059-11065.
Bastyr III, EJ and Lu, J., Diabetes 1993, 42 (Suppl.1) 97A.
Hsieh et al., Proc Natl Acad. Sci USA, 1991, 88, 9315-9319.
Hsieh et al, J. Biol. Chem., 1993, 268, 15118-15126.
Murray et al, J. Biol Chem, 1993, 268, 15847-15853.
Bilder et al., J. Pharmaceol. Exp. Ther., 1990, 252, 526-530.
Matsumoto, H. and Sasaki, Y., Biochem. Biophys. Res. Commun., 1989, 158, 105-109.
Yan, S-F, et al., J. Biol. Chem, 2000, 275, 16, 11921-11928.
Ren, S. et al., Am. J. Physiol., 2000, 278, (4 pt. 1) E656-E-662.
Muid, R.E. et al, FEBS Lett., 1990, 293, 169-172.
Sonoki H. et al, Kokyu-To Junkan 1989, 37, 669-674.
Kobayashi, et al., Amer. Phys. Soc, 1994, H1214-H1220.
Toullec, D et al., J. Biol. Chem., 1991, 266, 15771-15781.
Karasik, A. et al., J. Biol. Chem., 1990, 265, 10226-10231.
Chen K.S. et al., Trans Assoc. Am Physicians, 1991, 104, 206-212.
Chin, J.E. et al., J. Biol. Chem., 1993, 268, 6338-6347.
Lee, T-S, et al., J Clin Invest. 1989, 83, 90-94.
Lee T-S et al, Proc Natl Acad Sci USA 1989, 86.
Craven, P.A. and Derubertis, F.R., J. Clin Invest 1989, 87, 1667-1675.
Wolf, B.A. et al., J. Clin Invest., 1991, 87, 31-38.
Tesfamariam B. et al., J. Clin Invest 1991, 87, 1643-1648.
Ishii, H. et al, Science, 1996, 272, 728-731.
X. Gu et al, Circ. Res., 1994, 75, 926.
R. H. Strasser et al., Circulation, 1996, 94, 1551.
H. Wakasaki et al., Proc. Natl Acad. Science, USA 1997, 94, 9320.
Twoemy, B. et al, Biochem Biophys Res. Comun 1990, 171, 1087-1092.
Mulqueen et al., Agents Actions 1992, 37, 85-89.
Nechushtan H et al, Blood 2000(Mar.) 95, 5, 1752-1757.
Nagpala et al., J. Cell Physiol., 1996, 2, 249-55.
Dekker et al, Biochem J. 2000, 347, 285-289.
Slater et al, Biorg and Med Chem 1999, 7, 1067-1074.
Rabbi et al, Virology, 1998, 245, 2, 257-269.
Leitges, M et al., Science, 1996, 273, 5276, 788-789.
Horn et al, J. Invest. Dermatol., 1987, 88, 220-222.
Raynaud F. and Evain-Brion, D., Br. J. Dermatol., 1991, 124, 542-546.
Hegemann et al., Arch Dermatol Res., 1991, 283, 456-460.
Bollag et al., J. Invest. Dermatol., 1993, 100, 240-246.
Rottenberg et al., Biochem Mol. Aspects Sel. Cancer, 1991, 1, 25-73.
Ahmad et al., Molecular Pharmacology, 1993, 43, 858-862.
Meyer et al, Int. J. Cancer, 1989, 43, 851-856.
Akinagaka et al., Cancer Res., 1991, 51, 4888-4892.
Sauma et al., Cell Growth Differ. , 1996, 7, 5, 587-594.
Konig et al., Blood, 1997, 90, 10, suppl. 1 pt. 2.
Danso et al, Proc Am. Assoc. Cancer Res., 1997, 38, 88 Meet, 92.
Harrington et al., J Biol. Chem., 1997, 272, 11, 7390-7397.
Begemann et al., Anti-Cancer Res. (Greece) 1998, 18, 4A, 2275-2282.
Teicher et al.., Proc Am. Assoc Cancer Res., 1998, 39, 89 Meet., 384.
Teicher et al., Clinical Cancer Research, 2001, 7, 634-640.
Huang K P, Trends Neuroscience, 1989, 12, 425-432.
Shimohama et al., Neurology, 1993, 43, 1407-1413.
Hara et al., J. Cereb Blood Flow Metab., 1990, 10, 646-653.
Shibata et al., Brain Res., 1992, 594, 290-294.
Beldhuis et al., Neuroscience 1993, 55, 4, 965-73.
Miletic et al., Neuroscience Lett 2000, 288, 3, 199-202.
Chen et al., Science, 1997, 278, 5336, 279-283.
Embi et al, Eur. J. Biochem 1980, 107, 519-527.
Cross et al., Biochemical Journal, 1994, 303, 21-26.
Villar-Palasi C. and Larner, J. Biochem. Biophys. Acta 1960, 39, 171-173.
Parker et al., Eur J. Biochem, 1983, 130, 227-234.
Cohen et al., Biochem Soc Trans 1993, 21, 555-567.
Srivastava et al., Mol. and Cellular Biochem 1998, 182, 135-141.
Chen et al., Diabetes, 1994, 43, 1234-1241.
Eldar-Finkelman et al, PNAS 1996, 93, 10228-10233.
Eldar-Finkelman and Krebs.. PNAS, 1997, 94, 9660-9664.
Eldar-Finkelman et al,, Diabetes, 1999, 48, 1662-1666.
Gat et al., Cell, 1998, 95, 604-614.
Hoeflich et al., Nature, 2000, 406, 86-90.
Pap and Cooper, J. Biol. Chem., 1998, 273, 19929-19932.
D'Mello et al., Exp. Cell Res., 1994, 211, 332-338.
Nonaka and Chuang, Neuroreport, 1998, 9(9) 2081-2084.
Hong et al, J. Biol. Chem., 1997, 272, (40), 25326-32.
Ikeda et al., EMBO J., 1998, 17, 1371-1384.
Eastman et al., Curr Opin., Cell Biol., 1999, 11, 233.
Cotter et al., Neuroreport, 1998, 9, 1379-1383.
Lijam et al., Cell, 1997, 90, 895-905.
Manji et al., Ju. Clin. Psychiatry, 1990, 60 (SUPPL2) 27-39.
Zhu et al., Synthesis of Quinolinly/Isoquinolinyl (A) Pyrrolo(3,4-C) Carbazoles as Cyclin D1/CDK4 Inhibitors Bioorganic and Medicinal Chemistry Letters, Oxford, GB, vol. 13, Apr. 1, 2003, pp. 1231-1235 XP002255246.
Davis et al, “Inhibitors of Protein Kinase C11,2,3-Bixarylmaleimdes” Journal of Medicinal Chemistry, American Chemical Society, Washington, DC US, vol. 35, No. 1, 1992, pp. 177-184.
Conway Bruce
Demarest Keith
Hecker Leonard R.
Maryanoff Bruce E.
McComsey David F.
Janssen Pharmaceutica NV
Saeed Kamal A
Stercho Yuny P.
LandOfFree
Substituted pyrrolines as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolines as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolines as kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130501